MiNK, C-Further partner on cell therapy for pediatric cancers

 

MiNK Therapeutics, C-Further partner on PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers with up to $1.1M IND funding

• Collaboration includes up to approximately $1.1 million in non-dilutive IND-enabling funding from C-Further.
• MiNK obtains rights to meaningful double-digit downstream commercial revenue participation under the C-Further collaboration.

https://finviz.com/quote.ashx?t=INKT&p=d